

NOTIFICATION PURSUANT TO

18 V.S.A. § 4637(c)

Subject: Notification Pursuant to 18 V.S.A. § 4637(c)

To the Office of the Attorney General of Vermont:

On March 5, 2024, Genentech USA, Inc. ("Genentech") notified the Office of the Attorney General of Vermont of a new prescription drug, Rozlytrek 50 mg Oral Pellets, pursuant to § 4637(b). Genentech hereby notifies the Attorney General of Vermont of the following additional information, pursuant to § 4637(c):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC (Wholesale Acquisition Cost) (As of the Date of Commercial Availability)
Rozlytrek 50 mg Oral Pellets	50242-0623-42	March 04, 2024	\$ 4676.36

Description of the marketing and pricing plans used in the launch of Rozlytrek 50 mg Oral Pellet in the United States and internationally:

Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers and - in some cases - patients about the approved indication(s), efficacy and safety data contained within the medicine's FDA approved label.

We take decisions related to the prices of our medicines very seriously. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn't prevent our medicines getting to people who need them.

Rozlytrek 50 mg Oral Pellets was not granted either breakthrough designation or priority review.

The estimated volume of patients who may be prescribed Rozlytrek 50 mg Oral Pellets:

Genentech does not publicly disclose the estimated volume of patients who may be prescribed **Rozlytrek 50 mg Oral Pellets**

The date and price of acquisition if the drug was not developed by the manufacturer:

Rozlytrek 50 mg Oral Pellets was developed by Genentech USA Inc. and was not acquired from a third party.